Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8.
Presenter
Heinz-Josef Lenz, MD
University of Southern California, Norris Comprehensive Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Oral Abstract Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03414983
DOI
10.1200/JCO.2022.40.4_suppl.008
Abstract #
8
Abstract Disclosures
Similar Videos & Slides
Speaker: Jonathan M. Marron, MD, MPH, FAAP
Videos & Slides
2020 ASCO Virtual Scientific Program
Impact of empirically eliminating 5-fluorouracil (5-FU) bolus and leucovorin (LV) in patients with metastatic colorectal cancer (mCRC) receiving first-line treatment with mFOLFOX6.
Speaker: Alexa Basilio, PharmD
Videos & Slides
2015 Gastrointestinal Cancers Symposium
RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp).
Speaker: Josep Tabernero, MD, PhD
Videos & Slides
2014 ASCO Annual Meeting
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).
Speaker: Alan P. Venook, MD